Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs

Vaccine

Volumn 25, Issue 44, 2007, Pages 7674-7686

  Giunchetti, Rodolfo Cordeiro ^a,b   Corrêa Oliveira, Rodrigo ^b   Martins Filho, Olindo Assis ^b   Teixeira Carvalho, Andréa ^a,b   Roatt, Bruno Mendes ^a   de Oliveira Aguiar Soares, Rodrigo Dian ^a   de Souza, Juliana Vitoriano ^a   das Dores Moreira, Nádia ^a   Malaquias, Luiz Cosme Cotta ^c   Mota e Castro, Luciana Lisboa ^b   de Lana, Marta ^a   Reis, Alexandre Barbosa ^a,b  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSIDADE VALE DO RIO DOCE   (Brazil)

Author keywords

Canine visceral leishmaniasis; Cell and humoral immune response; Saponin adjuvant

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LEISHMANIA VACCINE; LYMPHOCYTE ANTIGEN; NITRIC OXIDE; PROTOZOAL PROTEIN; SAPONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DOG; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LEISHMANIA BRAZILIENSIS; LEISHMANIA CHAGASI; LEISHMANIASIS; LYMPHOCYTE; MALE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; B-LYMPHOCYTES; DOG DISEASES; DOGS; FEMALE; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; MALE; NITRIC OXIDE; PROTOZOAN VACCINES; SAPONINS; T-LYMPHOCYTE SUBSETS; VACCINES, INACTIVATED;

EID: 35148881309     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.009     Document Type: Article

References (60)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27 (2004) 305-318
2. Evans T.G., Vasconcelos I.A., Lima J.W., Teixeira J.M., McAullife I.T., Lopes U.G., et al. Canine visceral leishmaniasis in northeast Brazil: assessment of serodiagnostic methods. Am J Trop Med Hyg 42 (1990) 118-123
3. Tesh R.B. Control of zoonotic visceral leishmaniasis: is it time to change strategies?. Am J Trop Med Hyg 52 (1995) 287-292
4. Braga M.D., Coelho I.C., Pompeu M.M., Evans T.G., MacAullife I.T., Teixeira M.J., et al. Controle do calazar canino: comparação dos resultados de um programa de eliminação rápida de cães sororreagentes por ensaio imuno-enzimático com outro de eliminação tardia de cães sororreagentes por teste de imunofluorescência indireta de eluato de papel filtro. Rev Soc Bras Med Trop 31 (1998) 419-424
5. Franca-Silva J.C., da Costa R.T., Siqueira A.M., hado-Coelho G.L., da Costa C.A., Mayrink W., et al. Epidemiology of canine visceral leishmaniosis in the endemic area of Montes Claros Municipality, Minas Gerais State, Brazil. Vet Parasitol 111 (2003) 161-173
6. Palatnik-de-Sousa C.B., dos Santos W.R., Franca-Silva J.C., da Costa R.T., Reis A.B., Palatnik M., et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am J Trop Med Hyg 65 (2001) 510-517
7. Hommel M., Jaffe C.L., Travi B., and Milon G. Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Ann Trop Med Parasitol 89 1 (1995) 55-73
8. Webb J.R., Kaufmann D., Campos-Neto A., and Reed S.G. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol 157 (1996) 5034-5041
9. Wilson M.E., Young B.M., Andersen K.P., Weinstock J.V., Metwali A., Ali K.M., et al. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun 63 (1995) 2062-2069
10. Webb J.R., Campos-Neto A., Ovendale P.J., Martin T.I., Stromberg E.J., Badaro R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66 (1998) 3279-3289
11. Dole V.S., Raj V.S., Ghosh A., Madhubala R., Myler P.J., and Stuart K.D. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine 19 (2000) 423-430
12. Mauel J. Vaccination against Leishmania infections. Curr Drug Targets Immune Endocr Metabol Disord 2 (2002) 201-226
13. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Seiky Y., et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and non-human primate models of the human disease. Infect Immun 69 (2001) 4103-4108
14. Brodskyn C., de Oliveira C.I., Barral A., and Barral-Netto M. Vaccines in leishmaniasis: advances in the last five years. Expert Rev Vaccines 2 (2003) 705-717
15. Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol 100 (2001) 87-103
16. Dunan S., Frommel D., Monjour L., Ogunkolade B.W., Cruz A., and Quilici M. Vaccination trial against canine visceral leishmaniasis. Phocean Veterinary Study Group on Visceral Leishmaniasis. Parasite Immunol 11 (1989) 397-402
17. Monjour L., Vouldoukis I., Ogunkolade B.W., Hetzel C., Ichen M., and Frommel D. Vaccination and treatment trials against murine leishmaniasis with semi-purified Leishmania antigens. Trans R Soc Trop Med Hyg 82 (1988) 412-415
18. da Silva V., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., Palatnik M., et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 19 (2000) 1082-1092
19. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante RN). Vaccine 20 (2002) 3277-3284
20. Lemesre J.L., Holzmuller P., Cavaleyra M., Goncalves R.B., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 (2005) 2825-2840
21. Lemesre J.L., Holzmuller P., Goncalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25 (2007) 4223-4234
22. Jeronimo S.M., Higgs E., Vedvick T., Mann B.J., Jernigan J., Petri W.A., et al. Identification of Leishmania chagasi antigens recognized by human lymphocytes. J Infect Dis 172 (1995) 1055-1060
23. Ravindran R., and Ali N. Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis. Curr Mol Med 4 (2004) 697-709
24. Mayrink W., Genaro O., Silva J.C., da Costa R.T., Tafuri W.L., Toledo V.P., et al. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mem Inst Oswaldo Cruz 91 (1996) 695-697
25. Lasri S., Sahibi H., Sadak A., Jaffe C.L., and Rhalem A. Immune responses in dogs vaccinated with autoclaved Leishmania major promastigotes. Vet Res 30 (1999) 441-449
26. Panaro M.A., Acquafredda A., Lisi S., Lofrumento D.D., Mitolo V., Sisto M., et al. Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes. Comp Immunol Microbiol Infect Dis 24 (2001) 187-195
27. Mohebali M., Khamesipour A., Mobedi I., Zarei Z., and Hashemi-Fesharki R. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine 22 (2004) 4097-4100
28. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
29. Reis A.B., Martins-Filho O.A., Teixeira-Carvalho A., Carvalho M.G., Mayrink W., Franca-Silva J.C., et al. Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Res Vet Sci 81 (2006) 68-75
30. Reis A.B., Teixeira-Carvalho A., Vale A.M., Marques M.J., Giunchetti R.C., Mayrink W., et al. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol 112 (2006) 102-116
31. Reis A.B., Carneiro C.M., Carvalho M.G., Teixeira-Carvalho A., Giunchetti R.C., Mayrink W., et al. Establishment of a microplate assay for flow cytometric assessment and it is use for the evaluation of age-related phenotypic changes in canine whole blood leukocytes. Vet Immunol Immunopathol 103 (2005) 173-185
32. 15N]-nitrate in biological fluids. Anal Biochem 126 (1982) 131-138
33. Gutman S.I., and Hollywood C.A. Simple, rapid method for determining nitrates and nitrites in biological fluids. Clin Chem 38 (1992) 2152
34. Keenan C.M., Hendricks L.D., Lightner L., Webster H.K., and Johnson A.J. Visceral leishmaniasis in the German shepherd dog. I. Infection, clinical disease, and clinical pathology. Vet Pathol 21 (1984) 74-79
35. Giunchetti R.C., Mayrink W., Genaro O., Carneiro C.M., Correa-Oliveira R., Martins-Filho O.A., et al. Relationship between canine visceral leishmaniosis and the Leishmania (Leishmania) chagasi burden in dermal inflammatory foci. J Comp Pathol 135 (2006) 100-107
36. Lage R.S., Oliveira G.C., Busek S.U., Guerra L.L., Giunchetti R.C., Correa-Oliveira R., et al. Analysis of the cytokine profile in spleen cells from dogs naturally infected by Leishmania chagasi. Vet Immunol Immunopathol 115 (2007) 135-145
37. Reis A.B., Teixeira-Carvalho A., Giunchetti R.C., Guerra L.L., Carvalho M.G., Mayrink W., et al. Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi. Clin Exp Immunol 146 (2006) 303-311
38. Baneth G., and Shaw S.E. Chemotherapy of canine leishmaniasis. Vet Parasitol 106 (2002) 315-324
39. Noli C., and Auxilia S.T. Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet Dermatol 16 (2005) 213-232
40. Abranches P., Santos-Gomes G., Rachamim N., Campino L., Schnur L.F., and Jaffe C.L. An experimental model for canine visceral leishmaniasis. Parasite Immunol 13 (1991) 537-550
41. Barbieri C.L. Immunology of canine leishmaniasis. Parasite Immunol 28 (2006) 329-337
42. Carvalho E.M., Badaro R., Reed S.G., Jones T.C., and Johnson Jr. W.D. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 76 (1985) 2066-2069
43. Peruhype-Magalhaes V., Martins-Filho O.A., Prata A., Silva Lde A., Rabello A., Teixeira-Carvalho A., et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 146 (2006) 124-132
44. Rajput Z.I., Hu S.H., Xiao C.W., and Arijo A.G. Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B 8 (2007) 153-161
45. Santos W.R., de Lima V., de Souza E.P., Bernardo R.R., Palatnik M., and Palatnik de Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21 (2002) 30-43
46. Parra L.E., Borja-Cabrera G.P., Santos F.N., Souza L.O., Palatnik-de-Sousa C.B., and Menz I. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine 25 (2007) 2180-2186
47. Kensil C.R. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 13 (1996) 1-55
48. Fujiwara R.T., Vale A.M., Franca da Silva J.C., da Costa R.T., Quetz J.S., Martins-Filho O.A., et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 36 (2005) 827-838
49. Deplazes P., Smith N.C., Arnold P., Lutz H., and Eckert J. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol 17 (1995) 451-458
50. Bourdoiseau G., Bonnefont C., Hoareau E., Boehringer C., Stolle T., and Chabanne L. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs. Vet Immunol Immunopathol 59 (1997) 21-30
51. Courtenay O., Quinnell R.J., Garcez L.M., Shaw J.J., and Dye C. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 186 (2002) 1314-1320
52. Day M.J. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Vet Parasitol 147 (2007) 2-8
53. Muller I., Pedrazzini T., Kropf P., Louis J., and Milon G. Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells. Int Immunol 3 (1991) 587-597
54. Melby P.C., Yang Y.Z., Cheng J., and Zhao W. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun 66 (1998) 18-27
55. Castellino F., and Germain R.N. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol 24 (2006) 519-540
56. Pinelli E. Cytokines in canine visceral leishmaniasis. In: Schijns V.E.C.J., and Horzinek M.C. (Eds). Cytokines in veterinary medicine (1997), Utrecht University Press, Utrecht 217-247
57. Cobbold S., and Metcalfe S. Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens 43 (1994) 137-154
58. Whitley E.M., Bird A.C., Zucker K.E., and Wolfe L.G. Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines. Anticancer Res 15 (1995) 923-929
59. Radosevich T.J., Seregina T., and Link C.J. Effective suppression of class I major histocompatibility complex expression by the US11 or ICP47 genes can be limited by cell type or interferon-gamma exposure. Hum Gene Ther 14 (2003) 1765-1775
60. Khamesipour A., Rafati S., Davoudi N., Maboudi F., and Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 123 (2006) 423-438